Imunon, Inc. is a clinical-stage biotechnology company. Co. is focused on advancing a portfolio of treatments that harness the body's natural mechanisms across an array of human diseases. Co. is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon's DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. We show 8 historical shares outstanding datapoints in our coverage of IMNN's shares outstanding history.
Understanding the changing numbers of IMNN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like IMNN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching IMNN by allowing them to research IMNN shares outstanding history
as well as any other stock in our coverage universe. |
Free IMNN Email Alerts:
Video: Shares Outstanding Importance
